Literature DB >> 20620886

Management of physical health in patients with schizophrenia: international insights.

I B Chaudhry1, J Jordan, F-R Cousin, R Cavallaro, J M Mostaza.   

Abstract

This international meeting discussed the management of physical health in patients with schizophrenia in several countries including France, Spain, Germany, the UK and Italy. Physical health parameters, including weight, blood pressure, blood glucose, lipids and standard biochemical assessments are measured in many patients at the first hospital consultation. These reveal physical disorders such as obesity, hypertension, dyslipidaemia, the metabolic syndrome, substance abuse, cardiovascular disease, extrapyramidal symptoms, sexual dysfunction and diabetes in substantial proportions of patients. Psychiatrists consider switching antipsychotic therapy if excessive sedation, extrapyramidal symptoms, unacceptable weight gain, hyperglycaemia or dyslipidaemia occur. In general, switching is more likely to be considered for symptomatic adverse events than for laboratory abnormalities. Switching is discouraged by limited knowledge of protocols, the absence of guidelines and fears of relapse or reduced treatment adherence. The physical health of patients with schizophrenia receives much less attention in the community setting than in the hospital setting. Improved guidelines, protocols, resources and support are needed to improve the physical health of patients in the community. Copyright (c) 2010 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20620886     DOI: 10.1016/S0924-9338(10)71705-3

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  5 in total

1.  The impact of pharmacological and non-pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta-review of meta-analyses of randomized controlled trials.

Authors:  Davy Vancampfort; Joseph Firth; Christoph U Correll; Marco Solmi; Dan Siskind; Marc De Hert; Rebekah Carney; Ai Koyanagi; André F Carvalho; Fiona Gaughran; Brendon Stubbs
Journal:  World Psychiatry       Date:  2019-02       Impact factor: 49.548

2.  Retrospective study of Japanese patients with schizophrenia treated with aripiprazole.

Authors:  Tetsuya Tanioka; Syoko Fuji; Mika Kataoka; Beth King; Masahito Tomotake; Yuko Yasuhara; Rozzano Locsin; Keiko Sekido; Kazushi Mifune
Journal:  ISRN Nurs       Date:  2012-08-30

Review 3.  Health promotion lifestyle interventions for weight management in psychosis: a systematic review and meta-analysis of randomised controlled trials.

Authors:  Elena Bonfioli; Loretta Berti; Claudia Goss; Francesca Muraro; Lorenzo Burti
Journal:  BMC Psychiatry       Date:  2012-07-12       Impact factor: 3.630

4.  Dental conditions in inpatients with schizophrenia: a large-scale multi-site survey.

Authors:  Hideaki Tani; Hiroyuki Uchida; Takefumi Suzuki; Yumi Shibuya; Hiroshi Shimanuki; Koichiro Watanabe; Ryosuke Den; Masahiko Nishimoto; Jinichi Hirano; Hiroyoshi Takeuchi; Shintaro Nio; Shinichiro Nakajima; Ryosuke Kitahata; Takashi Tsuboi; Kenichi Tsunoda; Toshiaki Kikuchi; Masaru Mimura
Journal:  BMC Oral Health       Date:  2012-08-18       Impact factor: 2.757

5.  Neurological soft signs and cognition in the late course of chronic schizophrenia: a longitudinal study.

Authors:  Christina J Herold; Céline Z Duval; Johannes Schröder
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2020-05-16       Impact factor: 5.270

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.